RxDoctor Payments Data

Ethan Yalvac, MD

Cardiovascular Disease · Santa Ana, CANPI 1942484852

Payments from drug & device makers

$27,342in general payments, 2019–2025

Across 986 payments — averaging $27.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$6K
  • AstraZeneca$2K
  • Novartis$2K
  • Johnson & Johnson$2K
  • Medtronic$1K
  • Boehringer Ingelheim$1K
  • plus $13K from 54 others

What the payments were for

  • Speaking & faculty fees$9003%
  • Food & beverage$25,78994%
  • Education$5342%
  • Gifts$750%
  • Entertainment$430%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biotronik Inc.74$5,643
AstraZeneca57$2,216
Novartis138$2,192
Johnson & Johnson89$1,606
Medtronic(2 entities)43$1,215
Boehringer Ingelheim60$1,150
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)60$1,149
Amgen54$1,116
Shockwave Medical, Inc8$945
E.r. Squibb & Sons, L.L.C.60$916
Abbott13$795
Abiomed13$712
Merck39$663
Novo Nordisk34$602
Cardiovascular Systems Inc.14$509
Boston Scientific12$414
Bard Peripheral Vascular, Inc.6$388
Pfizer21$373
Astellas Pharma US Inc6$365
Sanofi-aventis U.S. LLC21$342
Scpharmaceuticals Inc.13$317
Esperion Therapeutics, Inc.18$285
Cardiva Medical, Inc.8$275
Bayer15$257
Impulse Dynamics (USA) Inc.8$249
Chiesi USA, Inc.8$231
Tactile Systems Technology Inc13$212
Portola Pharmaceuticals, LLC6$173
Amarin Pharma, Inc.10$168
Stryker1$147
Siemens Medical Solutions USA, Inc.2$131
Acutus Medical, Inc.1$130
Regeneron Healthcare Solutions, Inc.6$114
Alnylam Pharmaceuticals Inc.5$106
Kestra Medical Technology Services, Inc.5$98
Opsens Inc.3$95
Trisalus Life Sciences, Inc.1$87
Kiniksa Pharmaceuticals International, PLC4$83
Actelion Pharmaceuticals US, Inc.5$82
Recor Medical Inc2$74
Otsuka America Pharmaceutical, Inc.3$67
Kiniksa Pharmaceuticals, Ltd.3$59
ZOLL Circulation Inc1$56
Heartflow, Inc.2$53
Venclose Inc.3$47
Angiodynamics, Inc.1$46
Bardy Diagnostics, Inc.2$43
Arbor Pharmaceuticals, Inc.2$35
GE HealthCare1$31
Teleflex LLC1$31
Cardinal Health 200 LLC1$30
Getinge USA Sales, LLC1$29
Ionis Pharmaceuticals, Inc.1$28
Lilly USA, LLC1$28
Cvrx, Inc.1$25
Lexicon Pharmaceuticals, Inc.1$21
Cleerly, Inc.1$20
Sun Pharmaceutical Industries Inc.1$19
Bsn Medical Inc1$16
Biocompatibles, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,342 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$720,132
Medicare patients
1,398
Services billed
5,222

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban532$668,347
EntrestoSacubitril/Valsartan198$233,925
XareltoRivaroxaban169$211,810
Repatha SureclickEvolocumab77$81,508
FarxigaDapagliflozin Propanediol46$60,261
Praluent PenAlirocumab38$40,151
JardianceEmpagliflozin44$39,442
OzempicSemaglutide29$38,616
BrilintaTicagrelor44$33,501
Ezetimibe376$11,353
Rosuvastatin Calcium548$8,579
Icosapent Ethyl26$8,423
Valsartan319$7,988
Metoprolol Succinate502$7,237
Atorvastatin Calcium696$6,830

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$373$668,347532 claims
NovartisEntresto$2,192$233,925198 claims
Johnson & JohnsonXarelto$1,606$211,810169 claims
AstraZenecaFarxiga, Brilinta$2,216$93,76290 claims
Boehringer IngelheimJardiance$1,150$39,44244 claims
Novo NordiskOzempic$602$38,61629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Santa Ana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →